Literature DB >> 31600454

Is a Universal Influenza Virus Vaccine Possible?

Raffael Nachbagauer1, Peter Palese1.   

Abstract

Influenza viruses remain a severe burden to human health because of their contribution to overall morbidity and mortality. Current seasonal influenza virus vaccines do not provide sufficient protection to alleviate the annual impact of influenza and cannot confer protection against potentially pandemic influenza viruses. The lack of protection is due to rapid changes of the viral epitopes targeted by the vaccine and the often suboptimal immunogenicity of current immunization strategies. Major efforts to improve vaccination approaches are under way. The development of a universal influenza virus vaccine may be possible by combining the lessons learned from redirecting the immune response toward conserved viral epitopes, as well as the use of adjuvants and novel vaccination platforms.

Entities:  

Keywords:  M2e; NP; hemagglutinin; influenza virus; neuraminidase; universal vaccine

Year:  2019        PMID: 31600454     DOI: 10.1146/annurev-med-120617-041310

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  26 in total

1.  Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Authors:  Maya Sangesland; Alba Torrents de la Peña; Seyhan Boyoglu-Barnum; Larance Ronsard; Faez Amokrane Nait Mohamed; Thalia Bracamonte Moreno; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; Musie Ghebremichael; Masaru Kanekiyo; Andrew Ward; Daniel Lingwood
Journal:  Immunity       Date:  2022-08-10       Impact factor: 43.474

2.  Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.

Authors:  Xueyong Zhu; Julianna Han; Weina Sun; Eduard Puente-Massaguer; Wenli Yu; Peter Palese; Florian Krammer; Andrew B Ward; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-20       Impact factor: 12.779

3.  Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes.

Authors:  Alec W Freyn; Julianna Han; Jenna J Guthmiller; Mark J Bailey; Karlynn Neu; Hannah L Turner; Victoria C Rosado; Veronika Chromikova; Min Huang; Shirin Strohmeier; Sean T H Liu; Viviana Simon; Florian Krammer; Andrew B Ward; Peter Palese; Patrick C Wilson; Raffael Nachbagauer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

4.  In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Influenza A based on neuraminidase protein.

Authors:  Mandana Behbahani; Mohammad Moradi; Hassan Mohabatkar
Journal:  In Silico Pharmacol       Date:  2021-05-11

5.  A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jonathan Shpigelman; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Paul J Chu; David Burkhart; Roman Schoener; Takaji Matsutani; Dennis A Carson; Maripat Corr; Tomoko Hayashi
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 6.  Host immune response-inspired development of the influenza vaccine.

Authors:  Angela Choi; Adolfo García-Sastre; Michael Schotsaert
Journal:  Ann Allergy Asthma Immunol       Date:  2020-04-20       Impact factor: 6.347

7.  Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem.

Authors:  Wenbo Jiang; Emily H Pilkington; Hannah G Kelly; Hyon-Xhi Tan; Jennifer A Juno; Adam K Wheatley; Stephen J Kent
Journal:  PLoS One       Date:  2020-11-02       Impact factor: 3.240

8.  Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor.

Authors:  Nicholas C Wu; Sarah F Andrews; Julie E Raab; Sarah O'Connell; Chaim A Schramm; Xintao Ding; Michael J Chambers; Kwanyee Leung; Lingshu Wang; Yi Zhang; John R Mascola; Daniel C Douek; Julie E Ledgerwood; Adrian B McDermott; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2020-07-02       Impact factor: 21.023

9.  New Points of Departure for More Global Influenza Vaccine Use.

Authors:  Irina Kiseleva
Journal:  Vaccines (Basel)       Date:  2020-07-23

Review 10.  Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection.

Authors:  Kayla Frank; Silke Paust
Journal:  Front Cell Infect Microbiol       Date:  2020-08-18       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.